Tag Archives: Stifel Nicolaus Weisel

New Source Energy Partners, L.P. Closes Over-Allotment Option

By Business Wirevia The Motley Fool

Filed under:

New Source Energy Partners, L.P. Closes Over-Allotment Option

OKLAHOMA CITY–(BUSINESS WIRE)– New Source Energy Partners L.P., a Delaware limited partnership (NYS: NSLP) (the “Partnership”), announced today that underwriters of its recently completed initial public offering have purchased an additional 250,000 common units at $20.00 per unit granted to them in the Underwriting Agreement dated February 7, 2013. New Source Energy Partners‘ initial public offering of 4,000,000 common units, representing limited partnership interests in New Source Energy Partners, closed on February 13, 2013.

Net proceeds received by the Partnership from the sale of the additional common units were approximately $4.65 million in the aggregate, after deducting underwriting discounts, commissions and expenses. The public now owns an approximate 54.8% limited partner interest in the Partnership.

Baird, Stifel Nicolaus Weisel, BMO Capital Markets and Oppenheimer & Co. acted as joint book-running managers for the offering. Janney Montgomery Scott, Stephens Inc. and Wunderlich Securities acted as co-managers for the offering. Copies of the prospectus related to the offering may be obtained from the underwriters as follows:

Robert W. Baird & Co. Incorporated

Attention: Syndicate Department

777 East Wisconsin Avenue

Milwaukee, WI 53202-5391

syndicate@rwbaird.com

(800) 792-2413

 

…read more
Source: FULL ARTICLE at DailyFinance

Realty Income Closes Common Stock Offering and Underwriters Exercise Full Over-Allotment Option

By Business Wirevia The Motley Fool

Realty Income Closes Common Stock Offering and Underwriters Exercise Full Over-Allotment Option

ESCONDIDO, Calif.–(BUSINESS WIRE)– Realty Income Corporation (Realty Income), The Monthly Dividend Company®, (NYS: O) , announced that in addition to the already upsized 15,000,000 share common stock offering that closed today, an additional 2,250,000 shares were purchased by the underwriters upon the exercise of their over-allotment option. With the full exercise of the over-allotment option, the total shares sold in the offering was 17,250,000 shares, and the total net proceeds from the offering, after underwriting discounts and offering expenses payable by the Company, is approximately $756 million.

The net proceeds from the offering will be used to repay borrowings under the Company’s $1.0 billion acquisition credit facility. Any remaining net proceeds will be used for other general corporate purposes and working capital, which may include additional acquisitions and the repayment of other debt.

All of the shares were sold by the Company. The underwriters for the offering were: BofA Merrill Lynch, Morgan Stanley, Wells Fargo Securities, Credit Suisse, Raymond James, RBC Capital Markets, and UBS Investment Bank (joint book-running managers), J.P. Morgan and Jefferies (co-lead managers), Baird, Barclays, BB&T Capital Markets, Citigroup, and Stifel Nicolaus Weisel (senior co-managers), and BNY Mellon Capital Markets, LLC and Piper Jaffray (co-managers).

A copy of the prospectus supplement and the related prospectus pertaining to the offering may be obtained from BofA Merrill Lynch, 222 Broadway, New York, New York 10038, Attn: Prospectus Department or email dg.prospectus_requests@baml.com; or Morgan Stanley, 180 Varick Street, 2nd Floor, New York, New York, 10014, Attn: Prospectus Department, telephone 1.866.718.1649 (toll-free) or email: prospectus@morganstanley.com; or Wells Fargo Securities, Attn: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, telephone: 1.800.326.5897 or email: cmclientsupport@wellsfargo.com.

These securities were offered pursuant to a Registration Statement that has become effective under the Securities Act. These securities are only offered by means of the prospectus included in the Registration Statement and the preliminary prospectus supplement related to the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction where the offer, solicitation, or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.


…read more
Source: FULL ARTICLE at DailyFinance

Pernix Therapeutics Completes Acquisition of Somaxon Pharmaceuticals, Inc.

By Business Wirevia The Motley Fool

Filed under:

Pernix Therapeutics Completes Acquisition of Somaxon Pharmaceuticals, Inc.

THE WOODLANDS, Texas–(BUSINESS WIRE)– Pernix Therapeutics Holdings, Inc. (“Pernix”) (NAS: PTX) today announced the completion of its acquisition of Somaxon Pharmaceuticals, Inc. (“Somaxon”) (NAS: SOMX) following the approval of the transaction by stockholders of Somaxon at the special meeting held on March 6, 2013.

Under the terms of the agreement announced on December 11, 2012, Pernix acquired all of the common stock of Somaxon in a stock-for-stock transaction with a total value of $25 million.

Somaxon stockholders will receive approximately 3,665,689 shares of Pernix common stock based on a per share price of Pernix’s common stock of $6.82, the volume-weighted average price of Pernix’s common stock over the 30-day period ending on the day immediately prior to today’s closing.

Cooper Collins, President and CEO of Pernix, said, “We are pleased to complete the acquisition of Somaxon, which is expected to continue to broaden our product portfolio. We expect Silenor to be an important addition to our product line that will be promoted by our sales force, and we may also develop Silenor as an OTC product.”

Silenor® (doxepin) is approved for the treatment of insomnia characterized by difficulty with sleep maintenance and is not a controlled substance. In clinical trials, Silenor demonstrated maintenance of sleep, including into the seventh and eighth hours of the night, with no meaningful evidence of next day residual effects and an overall adverse events profile that was comparable to placebo.

Stifel Nicolaus Weisel acted as financial advisor to Somaxon in the transaction.

Important Safety Information About Silenor

Because sleep disturbances may be caused by underlying physical and/or psychiatric disorders, symptomatic treatment of insomnia should be initiated only after a careful evaluation of the patient. The failure of insomnia to remit after 7-10 days of treatment may indicate the presence of a primary psychiatric and/or medical illness that should be evaluated.

Patients should only take Silenor when they are prepared to get a full night’s sleep. Silenor should be taken within 30 minutes of bedtime, and patients should confine their activities after ingestion to those necessary to prepare for bed. Patients should not consume alcohol or take other drugs that cause drowsiness with Silenor. Co-administration of monoamine oxidase inhibitors (MAOIs) with Silenor has not been studied and …read more
Source: FULL ARTICLE at DailyFinance

Realty Income Announces Pricing of Upsized 15.0 Million Share Common Stock Offering to Fund Property

By Business Wirevia The Motley Fool

Filed under:

Realty Income Announces Pricing of Upsized 15.0 Million Share Common Stock Offering to Fund Property Acquisitions

ESCONDIDO, Calif.–(BUSINESS WIRE)– Realty Income Corporation (Realty Income), The Monthly Dividend Company®, (NYS: O) , today announced that a public offering of 15,000,000 shares of the company’s common stock has been priced at a public offering price of $45.90 per share, and is expected to close March 11, 2013. Net proceeds from the offering, after underwriting discounts and estimated offering expenses payable by the company and assuming no exercise of the underwriters’ overallotment option, will be approximately $656.9 million. The offering was upsized from an original amount of 10,000,000 shares to the final offering size of 15,000,000 shares. The company has also granted the underwriters a 30-day option to purchase up to 2,250,000 additional shares of common stock to cover overallotments, if any. All of the shares are being sold by the company.

The company expects to use the net proceeds from the offering to repay borrowings under its $1.0 billion acquisition credit facility. Any remaining net proceeds will be used for other general corporate purposes and working capital, which may include additional acquisitions and the repayment of other debt.

The underwriters for the offering are BofA Merrill Lynch, Morgan Stanley, Wells Fargo Securities, Credit Suisse, Raymond James, RBC Capital Markets, and UBS Investment Bank (joint book-running managers), J.P. Morgan and Jefferies (co-lead managers), Baird, Barclays, BB&T Capital Markets, Citigroup, and Stifel Nicolaus Weisel (senior co-managers), and BNY Mellon Capital Markets, LLC and Piper Jaffray (co-managers).

A copy of the prospectus supplement and the related prospectus pertaining to the offering may be obtained, when available, from BofA Merrill Lynch, 222 Broadway, New York, New York 10038, Attn: Prospectus Department or email dg.prospectus_requests@baml.com; or Morgan Stanley, 180 Varick Street, 2nd Floor, New York, New York, 10014, Attn: Prospectus Department, telephone 1.866.718.1649 (toll-free) or email: prospectus@morganstanley.com; or Wells Fargo Securities, Attn: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, telephone: 1.800.326.5897 or email: cmclientsupport@wellsfargo.com.

These securities are offered pursuant to a Registration Statement that has become effective under the Securities Act. These securities are only offered by means of the prospectus included in the Registration Statement and the preliminary prospectus supplement related to the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction where the offer, solicitation, or sale …read more
Source: FULL ARTICLE at DailyFinance

Realty Income Corporation Announces Commencement of Public Offering of Common Stock

By Business Wirevia The Motley Fool

Filed under:

Realty Income Corporation Announces Commencement of Public Offering of Common Stock

ESCONDIDO, Calif.–(BUSINESS WIRE)– Realty Income Corporation (Realty Income), The Monthly Dividend Company®, (NYS: O) , today announced that it has commenced an underwritten public offering of 10,000,000 shares of common stock. The Company also plans to grant the underwriters a 30-day option to purchase up to 1,500,000 additional shares of common stock to cover overallotments, if any. The underwriters for the offering are: BofA Merrill Lynch, Morgan Stanley, Wells Fargo Securities, Credit Suisse, Raymond James, RBC Capital Markets, and UBS Investment Bank (joint book-running managers), J.P. Morgan and Jefferies (co-lead managers), Baird, Barclays, BB&T Capital Markets, Citigroup, and Stifel Nicolaus Weisel (senior co-managers), and BNY Mellon Capital Markets, LLC and Piper Jaffray (co-managers).

The Company expects to use the net proceeds from the offering to repay borrowings under its $1.0 billion acquisition credit facility, which were, and will be, used to fund real estate acquisitions.

A preliminary prospectus supplement and final prospectus supplement related to the public offering of these securities has been or will be filed with the Securities and Exchange Commission. Copies of the preliminary prospectus supplement and final prospectus supplement, when available, may be obtained from BofA Merrill Lynch, 222 Broadway, New York, New York 10038, Attn: Prospectus Department or email dg.prospectus_requests@baml.com; or Morgan Stanley, 180 Varick Street, 2nd Floor, New York, New York, 10014, Attn: Prospectus Department, telephone 1.866.718.1649 (toll-free) or email: prospectus@morganstanley.com; or Wells Fargo Securities, Attn: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, telephone: 1.800.326.5897 or email: cmclientsupport@wellsfargo.com.

These securities are offered pursuant to a Registration Statement that has become effective under the Securities Act. These securities are only offered by means of the prospectus included in the Registration Statement and the preliminary prospectus supplement related to the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction where the offer, solicitation, or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.


Forward-Looking Statements

Statements in this press release that are not strictly historical are “forward-looking” statements. Forward-looking statements involve known …read more
Source: FULL ARTICLE at DailyFinance